Pharmacogenetics and Schizophrenia

Adriana Elena Foster, Del D. Miller, Peter F Buckley

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Emergent pharmacogenetic studies indicate that the efficacy of antipsychotic medications in schizophrenia may be predicted through genetic analysis. There also is evidence that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain, glucose and lipid abnormalities, and tardive dyskinesia may be predicted by pharmacogenetic analysis in this patient population. In the future, this targeted approach with the choice of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic status may gain hold as new treatments are developed with even fewer side effects.

Original languageEnglish (US)
Pages (from-to)417-435
Number of pages19
JournalPsychiatric Clinics of North America
Volume30
Issue number3
DOIs
StatePublished - Sep 1 2007

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Pharmacogenetics and Schizophrenia'. Together they form a unique fingerprint.

  • Cite this

    Foster, A. E., Miller, D. D., & Buckley, P. F. (2007). Pharmacogenetics and Schizophrenia. Psychiatric Clinics of North America, 30(3), 417-435. https://doi.org/10.1016/j.psc.2007.04.004